The latest financial statement is for the quarter ending 2026-04-05.
| Cash Flow | 2026-04-05 | 2025-12-28 | 2025-09-28 | 2025-06-29 |
|---|---|---|---|---|
| Net loss | -38,258 | -35,041 | -53,769 | -44,266 |
| Depreciation, accretion and amortization | 9,370 | 8,437 | 9,398 | 8,829 |
| Stock-based compensation expense | 11,765 | 11,394 | 11,837 | 14,122 |
| Change in fair value of common stock warrants | -6,397 | -10,054 | -1,867 | 5,885 |
| Gain on bargain purchase of assets | - | 0 | 0 | 4,761 |
| Impairment and loss on disposal of long-lived assets | - | 0 | 0 | 0 |
| Interest expense (non-cash) | - | 0 | 9,222 | - |
| Others | 386 | 601 | 93 | -926 |
| Accounts and notes receivables | -4,359 | 1,576 | 1,807 | 982 |
| Inventory | 2,834 | -1,737 | 1,837 | 2,584 |
| Prepaid expenses and other assets | 1,252 | 530 | 1,320 | 675 |
| Accounts payable | -3,600 | -1,849 | 4,298 | -2,179 |
| Accrued expenses and compensation | -4,058 | 4,335 | 2,220 | -834 |
| Deferred revenue | -736 | -2,689 | -342 | 1,501 |
| Deferred tax liability | -241 | -170 | -452 | -650 |
| Other liabilities | -804 | -392 | -1,014 | -191 |
| Net cash used in operating activities | -33,072 | -26,999 | -25,526 | -25,859 |
| Purchase of property and equipment | 3,220 | 1,007 | 2,973 | 7,971 |
| Payment for business acquisition | 0 | 0 | 0 | 10,000 |
| Purchases of investments | 103,458 | 214,805 | 284,660 | 27,390 |
| Maturities of investments | 125,008 | 16,747 | 39,518 | 18,627 |
| Net cash provided by (used in) investing activities | 18,330 | -199,065 | -248,115 | -26,718 |
| Proceeds from issuance of common stock, net of issuance costs | - | 0 | - | - |
| Proceeds from exercise of common stock warrants | - | 0 | 232,106 | - |
| Payments of issuance costs related to common stock and warrant dividends | - | 1,082 | 5,995 | - |
| Proceeds from issuance of convertible senior notes and loan borrowing | - | 0 | 362,772 | 1,800 |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 612 | 0 | 711 |
| Payments of debt issuance costs | - | 1,275 | 9,900 | - |
| Payroll tax payments for shares withheld upon vesting of rsus | 1,663 | 1,688 | 2,002 | 1,092 |
| Repurchase of unvested restricted common stock | - | 0 | 0 | - |
| Purchase of capped calls | - | 0 | 45,288 | - |
| Purchase of routejade shares from non-controlling interest | 740 | - | - | - |
| Repurchase of common stock | - | 0 | 58,385 | 0 |
| Repayment of debt | -55 | -232 | -54 | -633 |
| Proceeds from the exercise of stock options | 0 | 209 | 2,351 | 0 |
| Payments of transaction costs related to common stock issuance | 0 | - | - | 0 |
| Net cash used in financing activities | -2,458 | -3,349 | 473,418 | -1,194 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -147 | -127 | -307 | 126 |
| Change in cash, cash equivalents, and restricted cash | -17,347 | -229,540 | 199,470 | -53,645 |
| Cash and cash equivalents and restricted cash, beginning of period | 107,979 | 337,519 | 138,049 | 191,694 |
| Cash and cash equivalents and restricted cash, end of period | 90,632 | 107,979 | 337,519 | 138,049 |
Enovix Corp (ENVX)
Enovix Corp (ENVX)